Alright, fellow drug hunters. Lets cut through the noise. The graveyard of drug discovery is littered with 'beautiful biology' that couldn't be drugged. My job? Find what can be drugged and prove it. And right now, my money's on 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
Target
15-PGDH. Not some esoteric transcription factor, but a bona fide enzyme. You know, something we can actually hit with a small molecule.
Rationale
Forget passive decline. Aging isn't just a slow fade; it's an active, enzymatically-driven assault on our tissues. 15-PGDH, this so-called 'gerozyme,' ramps up with age, systematically obliterating Prostaglandin E2 (PGE2) – our endogenous pro-regenerative signal. It's like having a saboteur in the system, constantly shifting the tissue microenvironment from 'repair' to 'decay.' We're not just losing regenerative capacity; we're actively destroying it.
Evidence
Stanford's data is compelling, not hand-wavy:
Age-Related Upregulation: 15-PGDH levels are significantly elevated in aged cartilage and muscle. Correlation, sure, but the next part is causation.
Regeneration via Inhibition: Hit 15-PGDH with a small molecule inhibitor in old mice, and boom: ~50% increase in muscle fiber diameter, full restoration of articular cartilage. That's not just slowing decline; that's reversing age-related degeneration.
PGE2 as the Effector: The mechanism is clear. Inhibiting 15-PGDH boosts local PGE2, which then rejuvenates local tissue stem cells. Clear target engagement, clear downstream effect.
Proposed Modality
Oral small molecule inhibitor. No gen